Pfizer Vfend
Executive Summary
Pfizer antifungal agent Vfend will be reviewed by FDA's Antiviral Drugs Advisory Committee Oct. 4 for treatment of invasive aspergillosis, serious Candida infections, infections caused by scedosporium and fusarium species, rare and refractory infections, and empirical treatment of febrile neutropenia. NDA for oral and I.V. voriconazole was submitted in November 2000. The meeting will begin at 8:30 at the Town Center Hotel in Silver Spring, Md